
GEMMABio Secures ARPA-H Funding to Advance AI-Driven Gene Editing
Philadelphia-based GEMMABio has secured federal funding from the Advanced Research Projects Agency for Health to develop precision genetic treatments for rare liver diseases. The initiative, titled the RAPID project, leverages AI-designed base-editing systems from Profluent Bio to target specific mutations responsible for life-threatening metabolic conditions.























